ADHD is a neurodevelopmental disorder characterized by hyperactivity, impulsivity, and inattention, which can severely impact an individual's ability to manage daily responsibilities.

Approximately 25% of ADHD patients do not respond effectively to current treatments, underscoring the urgent need for alternative therapeutic options.

Parker emphasized that repurposing amlodipine could provide a swift and effective treatment alternative for ADHD, leveraging its established safety record.

Amlodipine, a medication commonly used for managing blood pressure, has emerged as a promising alternative for reducing hyperactivity in patients with attention-deficit hyperactivity disorder (ADHD), as highlighted in a recent study published in Neuropsychopharmacology.

In contrast to current ADHD medications, which often lead to side effects such as appetite loss, amlodipine is well-tolerated and has an established safety profile.

Traditional ADHD treatments primarily involve stimulant medications like methylphenidate, which can have adverse effects and a risk of misuse, highlighting the necessity for safer alternatives.

The study also demonstrated that amlodipine can cross the blood-brain barrier, marking a significant finding as it allows the drug to directly influence brain function.

Conducted by researchers at the University of Surrey, the study tested five different drugs on rats exhibiting ADHD-like symptoms, with only amlodipine demonstrating a significant reduction in hyperactivity.

Genetic analyses have revealed a connection between ADHD and the calcium channels targeted by amlodipine, suggesting a relevant pathway for treatment.

Further supporting its potential, a UK-wide analysis of patient data revealed that individuals taking amlodipine experienced fewer mood swings and a decreased tendency for risk-taking behavior.

Researchers utilized zebrafish, which share about 70% of their genes with humans, to confirm amlodipine's ability to penetrate the blood-brain barrier and impact brain activity.

Dr. Matthew Parker, a co-author of the study, noted that amlodipine's existing approval and safety profile could facilitate its rapid deployment as a treatment option for ADHD.